Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Creating a framework for a successful launch: Who benefits
William McClellan, Center of Excellence Leader, Launch Excellence
Maneesh Gupta, Senior Principal, Brand & Commercial Strategy, IQVIA
Aug 14, 2018
  • Blogs
  • Creating a framework for a successful launch: Who benefits

When there is low product differentiation between drugs in the market, the role of the consumer becomes more significant and costlier to launch successfully.

This is the fourth blog in the five blog series: Creating a framework for a successful launch. IQVIA analyzed launches globally to identify common launch challenges and pitfalls. Four launch archetypes were identified, "science sells", "market shaping", "who benefits" and "emphasize the difference", each had very specific critical success factors.

The "who benefits" archetype is identified as a drug with low unmet need in the market and low product differentiation, the critical success factors are: 

  • Laser focused targeting (prescriber/patient)
  • Realistic expectations
  • Services to differentiate product
  • Consumer focus –access, co-pay offsets / direct-to-consumer (US)

Additional challenges for emerging biopharma include:

  • Partner with large company – reaching the consumer can be an expensive proposition.

This particular case study focuses on services to differentiate products and a consumer-focused campaign.

Who benefits: Vascepa and the hypertriglyceridemia market

Vascepa (icosapent ethyl) was approved in the U.S., in July 2012 and launched in January 2013 by Amarin. It is a purified form of omega-3, containing only EPA (eicosapentaenoic acid), and was approved for severe hypertriglyceridemia. The drug missed the hoped-for mixed dyslipidemia indication after a vote against approval from an FDA advisory committee. 

At the time of its launch, Vascepa was up against a marketed and branded prescription formulation of a blend of two omega-3 fatty acids, backed by big pharma. Other competitors included branded statins, the first of the generic statins, and over-the-counter omega-3 supplements. 

Amarin therefore needed to carve out a space for its product, and the strategy for the launch was to build out the brand and differentiate the product in the eyes of the consumer. 

Vascepa underperformed its competitors at launch.

Analysts predicted around $59 million in revenue for 2013 for Vascepa. However, the first-year sales were just $32 million. This represented around a fifth of the market, with the other four-fifths taken by the branded prescription formulation of omega-3. 

This was due to a lack of consumer awareness and understanding of the value of omega-3s in raised triglycerides, which led to fewer patient visits and fewer screenings than expected. In an attempt to raise awareness and improve its market share post-launch, Amarin launched an unbranded website, to educate about triglycerides.

Working through challenging times

At the time of the launch, Amarin was going through a period of transition, and was undecided what its future business strategy was going to be. At the same time, it was trying to convince the FDA that Vascepa was a new chemical entity (NCE), which would have extended the drug's regulatory exclusivity. 

When there is low product differentiation between drugs in the market, the role of the consumer becomes more significant, as does the value of direct-to-consumer campaigns. DTC promotion is a costly process, however, often involving a considerable spend on a television campaign. While Amarin understood the relevance of the consumer influence, as a smaller company it didn't have the financial clout required to push forward a full-blown DTC promotion. 

Amarin did not partner for the commercialization of Vascepa, possibly due to an inability to find one. It is impossible to say what would have happened had Amarin been able to partner. However, partnering with a larger company can often have a benefit for small companies that fall into the "who benefits" archetype – products with low unmet need and low product differentiation.

To get more insight into the “market shaping” archetype visit: A framework for successful biopharma launches for the recorded webinar, supported by a slide presentation.

More about the Authors:

  • William McClellan
    Center of Excellence Leader, Launch Excellence
    William is an expert in the field of pharmaceutical launch excellence with over 20 years of experience. He leads the Launch Center of Excellence for the U.S. at IQVIA where he focuses on launch readiness, tracking, and performance diagnostics utilizing patient data such as predictive modeling and quantitative and qualitative research.
  • Maneesh Gupta
    Senior Principal, Brand & Commercial Strategy, IQVIA
    Maneesh is a Senior Principal with Consulting Services at IQVIA. He focuses on launch, brand, and commercial strategy. He has been helping organizations excel at launches and become more customer centric for over 20 years. His papers on these topics have been published in several industry journals.
Contact Us